Tamoxifen therapy in a murine model of myotubular myopathy

45Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

Abstract

Myotubular myopathy (MTM) is a severe X-linked disease without existing therapies. Here, we show that tamoxifen ameliorates MTM-related histopathological and functional abnormalities in mice, and nearly doubles survival. The beneficial effects of tamoxifen are mediated primarily via estrogen receptor signaling, as demonstrated through in vitro studies and in vivo phenotypic rescue with estradiol. RNA sequencing and protein expression analyses revealed that rescue is mediated in part through post-transcriptional reduction of dynamin-2, a known MTM modifier. These findings demonstrate an unexpected ability of tamoxifen to improve the murine MTM phenotype, providing preclinical evidence to support clinical translation.

Cite

CITATION STYLE

APA

Maani, N., Sabha, N., Rezai, K., Ramani, A., Groom, L., Eltayeb, N., … Dowling, J. J. (2018). Tamoxifen therapy in a murine model of myotubular myopathy. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-07057-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free